The combination of aspirin and anti-PD-L1 or anti-CTLA4 therapies in various cancer types is also under investigation in a few ongoing clinical trials (NCT02659384 (phase 2 in ovarian cancer); NCT03245489 (phase 1 in head and neck cancer); NCT03396952 (phase 2 in melanoma)). This evidence concerns the gene CD274 and melanoma.